These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 9952358)

  • 1. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses.
    Markowitz M; Vesanen M; Tenner-Racz K; Cao Y; Binley JM; Talal A; Hurley A; Jin X; Chaudhry MR; Yaman M; Frankel S; Heath-Chiozzi M; Leonard JM; Moore JP; Racz P; Nixon DF; Ho DD
    J Infect Dis; 1999 Mar; 179(3):527-37. PubMed ID: 9952358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens.
    Rinaldo CR; Liebmann JM; Huang XL; Fan Z; Al-Shboul Q; McMahon DK; Day RD; Riddler SA; Mellors JW
    J Infect Dis; 1999 Feb; 179(2):329-36. PubMed ID: 9878015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults.
    Notermans DW; Pakker NG; Hamann D; Foudraine NA; Kauffmann RH; Meenhorst PL; Goudsmit J; Roos MT; Schellekens PT; Miedema F; Danner SA
    J Infect Dis; 1999 Oct; 180(4):1050-6. PubMed ID: 10479130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
    Zaunders JJ; Cunningham PH; Kelleher AD; Kaufmann GR; Jaramillo AB; Wright R; Smith D; Grey P; Vizzard J; Carr A; Cooper DA
    J Infect Dis; 1999 Aug; 180(2):320-9. PubMed ID: 10395845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
    Michelet C; Bellissant E; Ruffault A; Arvieux C; Delfraissy JF; Raffi F; Bazin C; Renard I; Sébille V; Chauvin JP; Dohin E; Cartier F
    Clin Pharmacol Ther; 1999 Jun; 65(6):661-71. PubMed ID: 10391672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
    AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus type-1 mRNA splicing pattern in infected persons is determined by the proportion of newly infected cells.
    Vesanen M; Markowitz M; Cao Y; Ho DD; Saksela K
    Virology; 1997 Sep; 236(1):104-9. PubMed ID: 9299622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.
    Goodgame JC; Pottage JC; Jablonowski H; Hardy WD; Stein A; Fischl M; Morrow P; Feinberg J; Brothers CH; Vafidis I; Nacci P; Yeo J; Pedneault L
    Antivir Ther; 2000 Sep; 5(3):215-25. PubMed ID: 11075942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial.
    Hoen B; Dumon B; Harzic M; Venet A; Dubeaux B; Lascoux C; Bourezane Y; Ragnaud JM; Bicart-See A; Raffi F; Beauvais L; Fleury H; Séréni D
    J Infect Dis; 1999 Oct; 180(4):1342-6. PubMed ID: 10479169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant reduction in HIV-1 plasma viral load but not in proviral infected cells during sub-optimal antiretroviral therapy.
    Riva E; Antonelli G; Solmone MC; Turriziani O; Narciso P; Tozzi V; Dianzani F
    J Biol Regul Homeost Agents; 2000; 14(1):1-3. PubMed ID: 10763882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
    Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
    Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of HIV-1 RNA suppression and its durability during treatment with zidovudine/lamivudine.
    Opravil M; Hill AM; DeMasi R; Dawson D
    Antivir Ther; 1998; 3(3):169-76. PubMed ID: 10682134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response.
    Connick E; Lederman MM; Kotzin BL; Spritzler J; Kuritzkes DR; St Clair M; Sevin AD; Fox L; Chiozzi MH; Leonard JM; Rousseau F; D'Arc Roe J; Martinez A; Kessler H; Landay A
    J Infect Dis; 2000 Jan; 181(1):358-63. PubMed ID: 10608789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy.
    Hirsch M; Steigbigel R; Staszewski S; Mellors J; Scerpella E; Hirschel B; Lange J; Squires K; Rawlins S; Meibohm A; Leavitt R
    J Infect Dis; 1999 Sep; 180(3):659-65. PubMed ID: 10438352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy.
    Günthard HF; Wong JK; Spina CA; Ignacio C; Kwok S; Christopherson C; Hwang J; Haubrich R; Havlir D; Richman DD
    J Infect Dis; 2000 Feb; 181(2):522-31. PubMed ID: 10669335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years.
    Günthard HF; Havlir DV; Fiscus S; Zhang ZQ; Eron J; Mellors J; Gulick R; Frost SD; Brown AJ; Schleif W; Valentine F; Jonas L; Meibohm A; Ignacio CC; Isaacs R; Gamagami R; Emini E; Haase A; Richman DD; Wong JK
    J Infect Dis; 2001 May; 183(9):1318-27. PubMed ID: 11294662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children.
    Spiegel HM; DeFalcon E; Ogg GS; Larsson M; Beadle TJ; Tao P; McMichael AJ; Bhardwaj N; O'Callaghan C; Cox WI; Krasinski K; Pollack H; Borkowsky W; Nixon DF
    J Infect Dis; 1999 Aug; 180(2):359-68. PubMed ID: 10395850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in T cell phenotype and human immunodeficiency virus type 1-specific cytotoxicity after potent antiretroviral therapy.
    Seth A; Markee J; Hoering A; Sevin A; Sabath DE; Schmitz JE; Kuroda MJ; Lifton MA; Hirsch MS; Collier AC; Letvin NL; McElrath MJ
    J Infect Dis; 2001 Mar; 183(5):722-9. PubMed ID: 11181148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of virus-specific immune responses in SHIV(KU)-infected macaques treated with PMPA.
    Kumar A; Buch S; Foresman L; Bischofberger N; Lifson JD; Narayan O
    Virology; 2001 Jan; 279(1):97-108. PubMed ID: 11145893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.